Combination of epigallocatechin and a synthetic agonist of retinoid X receptor-γ (RXRγ), known as 6-OH-11-O-hydroxyphenanthrene (IIF), was shown to reduce expression of epidermal growth factor receptor (EGFR) and invasion- associated markers of CD44, MMP2, and 9 in breast cancer cell lines MCF7, MCF7- TAM, and MDA- MB231 (76). Here, EGFR is linked to breast cancer.